Erster Patient der LION-1-Studie erhält Immunzelltherapie gegen neues Zielmolekül
Welcome to the Chair for Cellular Immunotherapy
Home of CAR T
At the Chair of Cellular Immunotherapy at the University Hospital Würzburg, we identify therapeutically relevant cancer targets and develop novel CAR T cell products using rapid, cost-effective, non-viral manufacturing methods. With extensive clinical trial experience, we translate innovative therapies from research into patient care.
We benefit from a strong network of research institutions and close ties to the biotech industry, including T-CURX, a biotech startup spun out of our chair, and the Fraunhofer Institute for Cell Therapy and Immunology (IZI). The Würzburg branch of Fraunhofer IZI, like our chair, is led by Prof. Michael Hudecek.
Your CAReer
We provide numerous opportunities for PhDs and MDs at all levels of their training to get involved in the fight against cancer and have an impact on the way we treat malignant diseases. We are recruiting individuals with expertise in immunology who are highly motivated to help us advance our research program.
Publications
Find all publications from our chair on PubMed
Latest publications
Jaeckel E, Friedman SL, Hudecek M, Protzer U.
Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases.
J Hepatol. 2025 Jun 20:S0168-8278(25)02274-3
Go to publication
De Angelis B, D'Amore ML, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz JR, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C.
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring.
Front Immunol. 2025 Apr 24;16:1567582
Go to publication
Hinckley-Boned A, Barbero-Jiménez C, Tristán-Manzano M, Maldonado-Perez N, Hudecek M, Justicia-Lirio P, Martin F.
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy.
J Immunother Cancer. 2025 Apr 29;13(4):e010702
Go to publication
Wegner VD, Feile A, Alb M, Hudecek M, Hewitt P, Mosig AS.
Short-Chain Fatty Acids Modulate Anti-ROR1 CAR T-Cell Function and Exhaustion in an Intestinal Adenocarcinoma-on-Chip Model.
Adv Healthc Mater. 2025 May;14(13):e2405003
Go to publication
Peter J, Toppeta F, Trubert A, Danhof S, Hudecek M, Däullary T.
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies.
Oncol Res Treat. 2025;48(5):265-279
Go to publication
Dragon AC, Bonifacius A, Lienenklaus S, Verboom M, Gerhards JP, Ius F, Hinze C, Hudecek M, Figueiredo C, Blasczyk R, Eiz-Vesper B. Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection.
Mol Ther. 2025 Mar 5;33(3):1031-1047
Go to publication
Fleischer A, Kurth S, Duell J, Topp M, Strunz PP, Mersi J, Rasche L, Sanges C, Hudecek M, Einsele H, Maatouk I.
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.
J Immunother Cancer. 2024 Dec 22;12(12):e009174
Go to publication
Jacobs JJL, Beekers I, Verkouter I, Richards LB, Vegelien A, Bloemsma LD, Bongaerts VAMC, Cloos J, Erkens F, Gradowska P, Hort S, Hudecek M, Juan M, Maitland-van der Zee AH, Navarro-Velázquez S, Ngai LL, Rafiq QA, Sanges C, Tettero J, van Os HJA, Vos RC, de Wit Y, van Dijk S.
A data management system for precision medicine.
PLOS Digit Health. 2025 Jan 9;4(1):e0000464
Go to publication
Gehrke L, Gonçalves VDR, Andrae D, Rasko T, Ho P, Einsele H, Hudecek M, Friedel SR.
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.
Int J Mol Sci. 2024 Dec 21;25(24):13685
Go to publication
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, van der Meer AD, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M.
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
J Immunotoxicol. 2024 Oct;21(sup1):S13-S28
Go to publication
Gehrke G, Seifert N, Spieler P, Verbruggen C, Seifert R, Toppeta F, Krick M, Doose S, Einsele H, Sauer M, Nerreter T
Direct visualization of chimeric antigen receptors on primary human T cells using dSTORM super-resolution microscopy
Front. Immunol., 16:1632823, 2025 August 1, Volume 16 – 2025
Go to publication
Contact person
Univ.-Prof. Dr. med.
Michael Hudecek
Director and Research Group Leader Translational CAR-T Research Program